<!DOCTYPE html><html lang="en"><head><title>Static News</title><meta charSet="utf-8"/><meta name="description" content="Static delayed Hacker News."/><meta name="theme-color" media="(prefers-color-scheme: light)" content="white"/><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1d1f21"/><meta name="viewport" content="width=device-width,initial-scale=1.0"/><meta name="application-name" content="Static News"/><meta name="apple-mobile-web-app-title" content="Static News"/><meta name="apple-mobile-web-app-capable" content="yes"/><meta name="mobile-web-app-capable" content="yes"/><meta name="apple-mobile-web-app-status-bar-style" content="#1d1f21"/><link rel="preload" href="styles.css?v=1708160453223" as="style"/><link rel="stylesheet" href="styles.css?v=1708160453223"/></head><body><div id="container"><div id="inner"><header><a href="/">Static News</a><a href="/about">about</a></header><div id="content"><div><div id="title"><a href="https://arstechnica.com/science/2024/02/big-pharma-spends-billions-more-on-executives-and-stockholders-than-on-rd/">Big Pharma spends billions more on executives and stockholders than on R&amp;D</a> <span class="domain">(<a href="https://arstechnica.com">arstechnica.com</a>)</span></div><div class="subtext"><span>PaulHoule</span> | <span>80 comments</span></div><br/><div><div id="39406765" class="c"><input type="checkbox" id="c-39406765" checked=""/><div class="controls bullet"><span class="by">monkburger</span><span>|</span><a href="#39407399">next</a><span>|</span><label class="collapse" for="c-39406765">[-]</label><label class="expand" for="c-39406765">[8 more]</label></div><br/><div class="children"><div class="content">Big Pharma&#x27;s profits are a result of taxpayer funded research via the NIH and others for drug discovery.<p><a href="https:&#x2F;&#x2F;www.ineteconomics.org&#x2F;perspectives&#x2F;blog&#x2F;us-tax-dollars-funded-every-new-pharmaceutical-in-the-last-decade" rel="nofollow">https:&#x2F;&#x2F;www.ineteconomics.org&#x2F;perspectives&#x2F;blog&#x2F;us-tax-dolla...</a><p>Big Pharma has a very powerful lobbying arm that is against Medicare negotiating down prices.</div><br/><div id="39407418" class="c"><input type="checkbox" id="c-39407418" checked=""/><div class="controls bullet"><span class="by">blackbear_</span><span>|</span><a href="#39406765">parent</a><span>|</span><a href="#39407145">next</a><span>|</span><label class="collapse" for="c-39407418">[-]</label><label class="expand" for="c-39407418">[5 more]</label></div><br/><div class="children"><div class="content">It is true that pharma companies take advantage of publicly funded research, but from there to brining a new drug on the market it takes further 10&#x2F;15 years and 100s million dollars of R&amp;D. A large portion of the cost comes from the fact that most of these projects prove infeasible and are abandoned during development or later during trials.<p>The vast majority of this effort remains unpublished, so I am not sure that the article you cite supports your argument. Most of the research mentioned in that article talks about possible associations between target and disease, which is just the earliest step of drug development.</div><br/><div id="39407725" class="c"><input type="checkbox" id="c-39407725" checked=""/><div class="controls bullet"><span class="by">consumer451</span><span>|</span><a href="#39406765">root</a><span>|</span><a href="#39407418">parent</a><span>|</span><a href="#39407666">next</a><span>|</span><label class="collapse" for="c-39407725">[-]</label><label class="expand" for="c-39407725">[1 more]</label></div><br/><div class="children"><div class="content">[delayed]</div><br/></div></div><div id="39407666" class="c"><input type="checkbox" id="c-39407666" checked=""/><div class="controls bullet"><span class="by">swores</span><span>|</span><a href="#39406765">root</a><span>|</span><a href="#39407418">parent</a><span>|</span><a href="#39407725">prev</a><span>|</span><a href="#39407145">next</a><span>|</span><label class="collapse" for="c-39407666">[-]</label><label class="expand" for="c-39407666">[3 more]</label></div><br/><div class="children"><div class="content">The thing is, pharma industry is clearly hugely profitable, so why doesn&#x27;t the government invest in a wide shotgun approach to fund half (or more) of the entire industry and in return take half (or more) of the profits to either keep as revenue or reinvest in pharma or in other healthcare?<p>(Obviously theoretically ideal economically would be if the government could just have a socialised department discovering and developing all new drugs needed with no profit margins, but then you lose out on benefits of competition, profit motives etc. so a split model makes sense, where they&#x27;re still private companies but the gov invests hugely in them - but in return for the fair share of profits, rather than so many current grants where the gov pays funding and it doesn&#x27;t even get them a good discount on buying the overpriced final drug.</div><br/><div id="39407691" class="c"><input type="checkbox" id="c-39407691" checked=""/><div class="controls bullet"><span class="by">NavinF</span><span>|</span><a href="#39406765">root</a><span>|</span><a href="#39407666">parent</a><span>|</span><a href="#39407145">next</a><span>|</span><label class="collapse" for="c-39407691">[-]</label><label class="expand" for="c-39407691">[2 more]</label></div><br/><div class="children"><div class="content">You could say that about any industry.<p>&quot;The thing is, the S&amp;P 500 is clearly hugely profitable, so why doesn&#x27;t the government invest in a wide shotgun approach to fund half (or more) of the entire S&amp;P 500 and in return take half (or more) of the profits to either keep as revenue or reinvest in the S&amp;P 500 or in other stock indexes?&quot;<p>Gov&#x27;t investment in any industry just because it&#x27;s profitable is a bad idea for obvious reasons.</div><br/><div id="39407715" class="c"><input type="checkbox" id="c-39407715" checked=""/><div class="controls bullet"><span class="by">swores</span><span>|</span><a href="#39406765">root</a><span>|</span><a href="#39407691">parent</a><span>|</span><a href="#39407145">next</a><span>|</span><label class="collapse" for="c-39407715">[-]</label><label class="expand" for="c-39407715">[1 more]</label></div><br/><div class="children"><div class="content">Sure, except that investing in the S&amp;P is just artificially inflating the economy as a whole, whereas my suggestion isn&#x27;t intended to be &quot;this is my advice for the most profitable use of a government $&quot;, it&#x27;s a suggestion for boosting a small part of the economy to speed up the development &#x2F; progress of new drugs as a societal benefit.</div><br/></div></div></div></div></div></div></div></div><div id="39407145" class="c"><input type="checkbox" id="c-39407145" checked=""/><div class="controls bullet"><span class="by">suzzer99</span><span>|</span><a href="#39406765">parent</a><span>|</span><a href="#39407418">prev</a><span>|</span><a href="#39407399">next</a><span>|</span><label class="collapse" for="c-39407145">[-]</label><label class="expand" for="c-39407145">[2 more]</label></div><br/><div class="children"><div class="content">&gt; Big Pharma has a very powerful lobbying arm that is against Medicare negotiating down prices.<p>I particularly liked how all the Congresspeople involved in writing that the government couldn&#x27;t negotiate drug prices into Medicare Part D immediately retired and went to work for the drug industry.</div><br/><div id="39407301" class="c"><input type="checkbox" id="c-39407301" checked=""/><div class="controls bullet"><span class="by">consumer451</span><span>|</span><a href="#39406765">root</a><span>|</span><a href="#39407145">parent</a><span>|</span><a href="#39407399">next</a><span>|</span><label class="collapse" for="c-39407301">[-]</label><label class="expand" for="c-39407301">[1 more]</label></div><br/><div class="children"><div class="content">When faced with a regulatory issue in the USA, I often look at EU regs for reference.  Here is their inquiry on the &quot;revolving door&quot; issue:<p><a href="https:&#x2F;&#x2F;www.ombudsman.europa.eu&#x2F;en&#x2F;decision&#x2F;en&#x2F;155953" rel="nofollow">https:&#x2F;&#x2F;www.ombudsman.europa.eu&#x2F;en&#x2F;decision&#x2F;en&#x2F;155953</a></div><br/></div></div></div></div></div></div><div id="39407399" class="c"><input type="checkbox" id="c-39407399" checked=""/><div class="controls bullet"><span class="by">mfiguiere</span><span>|</span><a href="#39406765">prev</a><span>|</span><a href="#39406368">next</a><span>|</span><label class="collapse" for="c-39407399">[-]</label><label class="expand" for="c-39407399">[2 more]</label></div><br/><div class="children"><div class="content">As mentioned by several comments, while one can argue that Big Pharma should spend more on R&amp;D, the title of the article is not so relevant.<p>From Apple financial statement for 2023 [1]:<p>- Spent on R&amp;D: $29.9B<p>- Spent on stockholders (dividends + buybacks): $92.6B<p>[1] <a href="https:&#x2F;&#x2F;www.apple.com&#x2F;newsroom&#x2F;pdfs&#x2F;fy2023-q4&#x2F;FY23_Q4_Consolidated_Financial_Statements.pdf" rel="nofollow">https:&#x2F;&#x2F;www.apple.com&#x2F;newsroom&#x2F;pdfs&#x2F;fy2023-q4&#x2F;FY23_Q4_Consol...</a></div><br/><div id="39407662" class="c"><input type="checkbox" id="c-39407662" checked=""/><div class="controls bullet"><span class="by">mplewis</span><span>|</span><a href="#39407399">parent</a><span>|</span><a href="#39406368">next</a><span>|</span><label class="collapse" for="c-39407662">[-]</label><label class="expand" for="c-39407662">[1 more]</label></div><br/><div class="children"><div class="content">We aren’t spending public money on Apple.</div><br/></div></div></div></div><div id="39406368" class="c"><input type="checkbox" id="c-39406368" checked=""/><div class="controls bullet"><span class="by">jimmar</span><span>|</span><a href="#39407399">prev</a><span>|</span><a href="#39407589">next</a><span>|</span><label class="collapse" for="c-39406368">[-]</label><label class="expand" for="c-39406368">[34 more]</label></div><br/><div class="children"><div class="content">&quot;Spending billions on stockholders&quot; is an odd way to frame giving profits to the owners (the shareholders). Does a small business owner spend money on herself when she makes a profit and moves money from the company account to her personal checking account?<p>Calling stockholders an expense misrepresents how businesses operate. &quot;Spending&quot; implies expense. Stock buybacks are a way of returning value to shareholders.</div><br/><div id="39406460" class="c"><input type="checkbox" id="c-39406460" checked=""/><div class="controls bullet"><span class="by">graemep</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39406428">next</a><span>|</span><label class="collapse" for="c-39406460">[-]</label><label class="expand" for="c-39406460">[22 more]</label></div><br/><div class="children"><div class="content">The point is that most of that profit comes from government incentives that are supposed to encourage R &amp; D. i.e. we pay several times more on drugs than we would without paying those incentives to the businesses, but only a small proportion of that extra money goes into R &amp; D. Its incredibly inefficient funding.<p>My take on that problem. There are others. <a href="https:&#x2F;&#x2F;pietersz.co.uk&#x2F;2007&#x2F;02&#x2F;patents-inefficient" rel="nofollow">https:&#x2F;&#x2F;pietersz.co.uk&#x2F;2007&#x2F;02&#x2F;patents-inefficient</a><p>I made the same point nearly 10 years before that with regard to R &amp; D vs marketing expenditure. Its not a new problem.</div><br/><div id="39407687" class="c"><input type="checkbox" id="c-39407687" checked=""/><div class="controls bullet"><span class="by">LudwigNagasena</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406460">parent</a><span>|</span><a href="#39406527">next</a><span>|</span><label class="collapse" for="c-39407687">[-]</label><label class="expand" for="c-39407687">[1 more]</label></div><br/><div class="children"><div class="content">Seems that the problem is with government incentives rather than with companies?</div><br/></div></div><div id="39406527" class="c"><input type="checkbox" id="c-39406527" checked=""/><div class="controls bullet"><span class="by">jimmar</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406460">parent</a><span>|</span><a href="#39407687">prev</a><span>|</span><a href="#39407242">next</a><span>|</span><label class="collapse" for="c-39406527">[-]</label><label class="expand" for="c-39406527">[10 more]</label></div><br/><div class="children"><div class="content">It seems like we want for-profit pharmaceutical corporations to act like non-profit institutions. Any idea why non-profit institutions haven&#x27;t risen in the world of pharmaceuticals?</div><br/><div id="39406563" class="c"><input type="checkbox" id="c-39406563" checked=""/><div class="controls bullet"><span class="by">tux3</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406527">parent</a><span>|</span><a href="#39406553">next</a><span>|</span><label class="collapse" for="c-39406563">[-]</label><label class="expand" for="c-39406563">[4 more]</label></div><br/><div class="children"><div class="content">It takes very many million dollars to run a clinical trial, why the rhetorical question?<p>It&#x27;s just funding. Not like non-profits are magically unable to have talent, or to achieve results.<p>No one&#x27;s giving away billions on a pharma non-profit when they could invest. Even though the result is sometimes similar for the investor.</div><br/><div id="39406602" class="c"><input type="checkbox" id="c-39406602" checked=""/><div class="controls bullet"><span class="by">jimmar</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406563">parent</a><span>|</span><a href="#39406776">next</a><span>|</span><label class="collapse" for="c-39406602">[-]</label><label class="expand" for="c-39406602">[1 more]</label></div><br/><div class="children"><div class="content">It wasn&#x27;t a rhetorical question. I could imagine an entity like the Gates Foundation proving seed funding to bootstrap a non-profit pharmaceutical company. That company could fund R&amp;D through sales of its newly developed medicines. No shareholders. No stock buybacks. But somehow this doesn&#x27;t seem to happen, at least not on a scale that reduces medical costs for consumers.</div><br/></div></div><div id="39406776" class="c"><input type="checkbox" id="c-39406776" checked=""/><div class="controls bullet"><span class="by">tomohelix</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406563">parent</a><span>|</span><a href="#39406602">prev</a><span>|</span><a href="#39406638">next</a><span>|</span><label class="collapse" for="c-39406776">[-]</label><label class="expand" for="c-39406776">[1 more]</label></div><br/><div class="children"><div class="content">&gt; It&#x27;s just funding.<p>And to have funding, you have to attract investors. How to attract investors? By making it quite profitable to invest in the company, i.e. making it profitable for the shareholders.<p>With enough money, you can do anything big pharma is doing. But how to get that money consistently is another question that have an uncomfortable answer. Plenty of startup and small biotech companies go bankrupt every year. This isn&#x27;t something you can do in a garage and turn it into a multibillion dollar business like software. Biopharma has too many regulations and rules to follow and it makes the entire field incredibly risky and less likely for a small and unattractive player to succeed, even if they are driven by passion.</div><br/></div></div><div id="39406638" class="c"><input type="checkbox" id="c-39406638" checked=""/><div class="controls bullet"><span class="by">throwaway14356</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406563">parent</a><span>|</span><a href="#39406776">prev</a><span>|</span><a href="#39406553">next</a><span>|</span><label class="collapse" for="c-39406638">[-]</label><label class="expand" for="c-39406638">[1 more]</label></div><br/><div class="children"><div class="content">I use to believe that. I then discover some private groups of people sharing a disease doing all kinds of trials. Nothing was to absurd. Almost brute forcing the problem. I thought a wiki written by mostly dead people was quite humbling.<p>There has to be some middle ground between the 2 branches of insanity?</div><br/></div></div></div></div><div id="39406553" class="c"><input type="checkbox" id="c-39406553" checked=""/><div class="controls bullet"><span class="by">santoshalper</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406527">parent</a><span>|</span><a href="#39406563">prev</a><span>|</span><a href="#39407242">next</a><span>|</span><label class="collapse" for="c-39406553">[-]</label><label class="expand" for="c-39406553">[5 more]</label></div><br/><div class="children"><div class="content">Or, we want for-profit pharmaceutical corporations to not take taxpayer dollars. You shouldn&#x27;t be able to have it both ways, but at least in the US, you can.</div><br/><div id="39406769" class="c"><input type="checkbox" id="c-39406769" checked=""/><div class="controls bullet"><span class="by">briffle</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406553">parent</a><span>|</span><a href="#39406690">next</a><span>|</span><label class="collapse" for="c-39406769">[-]</label><label class="expand" for="c-39406769">[2 more]</label></div><br/><div class="children"><div class="content">I don’t like the percentage profit they take in the US, they can sell a drug outside the US for $50, but charge $300 here. Either we are subsidizing other countries, or they are fleecing us for what they can get, often on the back of research funded by tax dollars.</div><br/><div id="39407084" class="c"><input type="checkbox" id="c-39407084" checked=""/><div class="controls bullet"><span class="by">tfourb</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406769">parent</a><span>|</span><a href="#39406690">next</a><span>|</span><label class="collapse" for="c-39407084">[-]</label><label class="expand" for="c-39407084">[1 more]</label></div><br/><div class="children"><div class="content">The latter, as these companies were perfectly profitable even if they wouldn&#x27;t charge inflated prices in the US. Not quite as profitable as currently, but still not going bankrupt.</div><br/></div></div></div></div><div id="39406690" class="c"><input type="checkbox" id="c-39406690" checked=""/><div class="controls bullet"><span class="by">s1artibartfast</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406553">parent</a><span>|</span><a href="#39406769">prev</a><span>|</span><a href="#39407242">next</a><span>|</span><label class="collapse" for="c-39406690">[-]</label><label class="expand" for="c-39406690">[2 more]</label></div><br/><div class="children"><div class="content">I hear this a lot, and I think that there is a fundamental misunderstanding of what&#x27;s going on.<p>People aren&#x27;t upset by for-profit grocery stores taking tax dollars in the form of food stamps. They aren&#x27;t upset by taxpayers giving money to for-profit hospitals to treat poor patients.<p>The government is paying a For profit company to do something that the government wants.<p>If the company would do it anyways, then of course I agree that the government shouldn&#x27;t pay for it.</div><br/><div id="39407098" class="c"><input type="checkbox" id="c-39407098" checked=""/><div class="controls bullet"><span class="by">tfourb</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406690">parent</a><span>|</span><a href="#39407242">next</a><span>|</span><label class="collapse" for="c-39407098">[-]</label><label class="expand" for="c-39407098">[1 more]</label></div><br/><div class="children"><div class="content">I think the difference is the extend of the profit. Big Pharma is incredibly profitable, while grocery stores are operating on very thin margins. Few people have a problem with a company doing business based on government expenditure, but specializing in maximizing profit from this reeks of profiteering.</div><br/></div></div></div></div></div></div></div></div><div id="39407242" class="c"><input type="checkbox" id="c-39407242" checked=""/><div class="controls bullet"><span class="by">bryanrasmussen</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406460">parent</a><span>|</span><a href="#39406527">prev</a><span>|</span><a href="#39406630">next</a><span>|</span><label class="collapse" for="c-39407242">[-]</label><label class="expand" for="c-39407242">[2 more]</label></div><br/><div class="children"><div class="content">&gt;we pay several times more on drugs than we would without paying those incentives to the businesses<p>that really depends on your economic system doesn&#x27;t it? In the more capitalist systems you pay what the market will bear and there is no consideration as to what the incentives are or aren&#x27;t.</div><br/><div id="39407295" class="c"><input type="checkbox" id="c-39407295" checked=""/><div class="controls bullet"><span class="by">ruined</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39407242">parent</a><span>|</span><a href="#39406630">next</a><span>|</span><label class="collapse" for="c-39407295">[-]</label><label class="expand" for="c-39407295">[1 more]</label></div><br/><div class="children"><div class="content">sometimes the market bears political incentives</div><br/></div></div></div></div><div id="39406630" class="c"><input type="checkbox" id="c-39406630" checked=""/><div class="controls bullet"><span class="by">s1artibartfast</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406460">parent</a><span>|</span><a href="#39407242">prev</a><span>|</span><a href="#39406907">next</a><span>|</span><label class="collapse" for="c-39406630">[-]</label><label class="expand" for="c-39406630">[7 more]</label></div><br/><div class="children"><div class="content">I feel like it is very easy to claim a top down command economy would be more efficient. On paper it makes sense. You have no stakeholder profit and no marketing budget. You just tell scientists what to make and doctors just prescribe whatever comes out the other end.<p>However, it is hard to find real examples that bear this out. I think that this View overestimates the capability of institutions and underestimates the utility of price signals and an open market with competition.</div><br/><div id="39407123" class="c"><input type="checkbox" id="c-39407123" checked=""/><div class="controls bullet"><span class="by">tfourb</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406630">parent</a><span>|</span><a href="#39406883">next</a><span>|</span><label class="collapse" for="c-39407123">[-]</label><label class="expand" for="c-39407123">[1 more]</label></div><br/><div class="children"><div class="content">Health systems in other (comparable) countries, where drug prices are centrally negotiated or outright set by government committees are vastly more efficient in terms of cost and generally produce better results in terms of health outcomes.<p>I.e. in my native Germany, health expenditure per capita is 2&#x2F;3 of what it is in the U.S. if faced with a life-threatening illness, I would vastly prefer to be in Germany than in the U.S. (with the possible exception of being super-rich and being able to buy top-of-the-line health care).</div><br/></div></div><div id="39406883" class="c"><input type="checkbox" id="c-39406883" checked=""/><div class="controls bullet"><span class="by">Hammershaft</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406630">parent</a><span>|</span><a href="#39407123">prev</a><span>|</span><a href="#39406995">next</a><span>|</span><label class="collapse" for="c-39406883">[-]</label><label class="expand" for="c-39406883">[1 more]</label></div><br/><div class="children"><div class="content">We could take a portion of those r&amp;d incentives and directly test and compare the cost &amp; output of government pharma research vs private research in a mixed model.</div><br/></div></div><div id="39406995" class="c"><input type="checkbox" id="c-39406995" checked=""/><div class="controls bullet"><span class="by">throwawayqqq11</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406630">parent</a><span>|</span><a href="#39406883">prev</a><span>|</span><a href="#39407109">next</a><span>|</span><label class="collapse" for="c-39406995">[-]</label><label class="expand" for="c-39406995">[1 more]</label></div><br/><div class="children"><div class="content">Price signals are just that, signals and there are others for sure, like regulation.<p>You dont have to imagine a top down economy and fail to find examples, when simply regulation would do the trick and keep some enterprise freedom.</div><br/></div></div><div id="39407109" class="c"><input type="checkbox" id="c-39407109" checked=""/><div class="controls bullet"><span class="by">6510</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406630">parent</a><span>|</span><a href="#39406995">prev</a><span>|</span><a href="#39406947">next</a><span>|</span><label class="collapse" for="c-39407109">[-]</label><label class="expand" for="c-39407109">[1 more]</label></div><br/><div class="children"><div class="content"><a href="https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;Trappist_beer" rel="nofollow">https:&#x2F;&#x2F;en.wikipedia.org&#x2F;wiki&#x2F;Trappist_beer</a><p>&gt; The beer must be brewed within the walls of a Trappist monastery, either by the monks themselves or under their supervision.<p>&gt; The brewery must be of secondary importance within the monastery and it should witness to the business practices proper to a monastic way of life.<p>&gt; The brewery is not intended to be a profit-making venture. The income covers the living expenses of the monks and the maintenance of the buildings and grounds. Whatever remains is donated to charity for social work and to help persons in need.<p>It&#x27;s funny to see above the suits and ties a layer of habits and scapulars[1]<p><a href="https:&#x2F;&#x2F;www.koningshoeven.nl&#x2F;media&#x2F;127&#x2F;compilatie-inkleding.png?width=960&amp;mode=resize" rel="nofollow">https:&#x2F;&#x2F;www.koningshoeven.nl&#x2F;media&#x2F;127&#x2F;compilatie-inkleding....</a></div><br/></div></div><div id="39406947" class="c"><input type="checkbox" id="c-39406947" checked=""/><div class="controls bullet"><span class="by">sudosysgen</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406630">parent</a><span>|</span><a href="#39407109">prev</a><span>|</span><a href="#39406942">next</a><span>|</span><label class="collapse" for="c-39406947">[-]</label><label class="expand" for="c-39406947">[1 more]</label></div><br/><div class="children"><div class="content">A lot of pharmaceuticals do however end up coming from what&#x27;s essentially a non-profit system. It doesn&#x27;t need to be a pure command economy.<p>The price signals are already broken. The people doing the research that is fundamental to pharmaceuticals are paid by grants which aren&#x27;t connected to the price signals. There is a market failure here.</div><br/></div></div></div></div></div></div><div id="39406428" class="c"><input type="checkbox" id="c-39406428" checked=""/><div class="controls bullet"><span class="by">haswell</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39406460">prev</a><span>|</span><a href="#39407204">next</a><span>|</span><label class="collapse" for="c-39406428">[-]</label><label class="expand" for="c-39406428">[2 more]</label></div><br/><div class="children"><div class="content">Plenty of companies do stock buybacks without also engaging in predatory pricing that customers are powerless to fight. The situation is even more problematic when you consider the lack of alternatives, and the often live-preserving nature of the product.<p>&gt; <i>Stock buybacks are a way of returning value to shareholders.</i><p>This is also a problematic framing that ignores the broader situation. And that’s the tricky thing about framing things. It’s easy to manipulate the narrative and obscure the unreasonableness of the underlying reality if you sufficiently narrow the frame.</div><br/><div id="39406742" class="c"><input type="checkbox" id="c-39406742" checked=""/><div class="controls bullet"><span class="by">s1artibartfast</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406428">parent</a><span>|</span><a href="#39407204">next</a><span>|</span><label class="collapse" for="c-39406742">[-]</label><label class="expand" for="c-39406742">[1 more]</label></div><br/><div class="children"><div class="content">I think this understates the power and options of the customers.<p>The typical alternative to receive what was state of the art care 10 years prior and off patent, and now 5% the price.  The unfortunate part is the desire for such products is so low, that most of the time they are discontinued.<p>It is essentially a tragedy of the commons in the US. Because all the costs are shared, every individual is happy to pay 20X for a product that is 10% better.</div><br/></div></div></div></div><div id="39407204" class="c"><input type="checkbox" id="c-39407204" checked=""/><div class="controls bullet"><span class="by">aknfffn</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39406428">prev</a><span>|</span><a href="#39407412">next</a><span>|</span><label class="collapse" for="c-39407204">[-]</label><label class="expand" for="c-39407204">[2 more]</label></div><br/><div class="children"><div class="content">The moral dilemma is profiting from disease and the ill-health of a population.<p>The only argument against publicly funded drug production is that profit seeking is more efficient and the societal outcome is improved by <i>not</i> funding a public body to do this.<p>As other comments highlight, not only do societies publicly fund research (eg C19), they provide a legal system that protects monopoly profits, and won’t use single-payer bargaining on price…<p>So when pharmaceuticals then drop more cash on executives and shareholders it’s natural to question turning Covid19, cancer, or obesity etc into a profit centre for the wealthiest in society</div><br/><div id="39407465" class="c"><input type="checkbox" id="c-39407465" checked=""/><div class="controls bullet"><span class="by">carlosjobim</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39407204">parent</a><span>|</span><a href="#39407412">next</a><span>|</span><label class="collapse" for="c-39407465">[-]</label><label class="expand" for="c-39407465">[1 more]</label></div><br/><div class="children"><div class="content">Profiting from hunger, those pesky cooks. Profiting from people freezing, those deplorable tailors...</div><br/></div></div></div></div><div id="39407412" class="c"><input type="checkbox" id="c-39407412" checked=""/><div class="controls bullet"><span class="by">darth_avocado</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39407204">prev</a><span>|</span><a href="#39406399">next</a><span>|</span><label class="collapse" for="c-39407412">[-]</label><label class="expand" for="c-39407412">[1 more]</label></div><br/><div class="children"><div class="content">Okay, but they also spend more money on sales and marketing than they do on RnD. Surely that can be considered as “spending”.</div><br/></div></div><div id="39406399" class="c"><input type="checkbox" id="c-39406399" checked=""/><div class="controls bullet"><span class="by">lcnPylGDnU4H9OF</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39407412">prev</a><span>|</span><a href="#39407336">next</a><span>|</span><label class="collapse" for="c-39406399">[-]</label><label class="expand" for="c-39406399">[1 more]</label></div><br/><div class="children"><div class="content">They led with mentioning executives, which is spending on employee salaries and bonuses. At any rate, I think it’s the same point to say “makes billions more in profit than they spend on R&amp;D”.</div><br/></div></div><div id="39407336" class="c"><input type="checkbox" id="c-39407336" checked=""/><div class="controls bullet"><span class="by">__loam</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39406399">prev</a><span>|</span><a href="#39406397">next</a><span>|</span><label class="collapse" for="c-39407336">[-]</label><label class="expand" for="c-39407336">[1 more]</label></div><br/><div class="children"><div class="content">Okay but stock buybacks should be illegal.</div><br/></div></div><div id="39407074" class="c"><input type="checkbox" id="c-39407074" checked=""/><div class="controls bullet"><span class="by">oaiey</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39406397">prev</a><span>|</span><a href="#39406693">next</a><span>|</span><label class="collapse" for="c-39407074">[-]</label><label class="expand" for="c-39407074">[1 more]</label></div><br/><div class="children"><div class="content">While that is true and how unregulated capitalism works, a society which enables capitalism (by laws, judges, ...) does not need to tolerate excessive profits on costs of its populations. Capitalism is not a law of nature. It is made by humans and can be adopted by the society. This is very common around the world.</div><br/></div></div><div id="39406693" class="c"><input type="checkbox" id="c-39406693" checked=""/><div class="controls bullet"><span class="by">petre</span><span>|</span><a href="#39406368">parent</a><span>|</span><a href="#39407074">prev</a><span>|</span><a href="#39407589">next</a><span>|</span><label class="collapse" for="c-39406693">[-]</label><label class="expand" for="c-39406693">[2 more]</label></div><br/><div class="children"><div class="content">Hopefully you&#x27;ll never need cancer treatment, because it would probably change your opinion.</div><br/><div id="39406764" class="c"><input type="checkbox" id="c-39406764" checked=""/><div class="controls bullet"><span class="by">s1artibartfast</span><span>|</span><a href="#39406368">root</a><span>|</span><a href="#39406693">parent</a><span>|</span><a href="#39407589">next</a><span>|</span><label class="collapse" for="c-39406764">[-]</label><label class="expand" for="c-39406764">[1 more]</label></div><br/><div class="children"><div class="content">Hopefully I will never have to test it, but I imagine cancer patients are also glad they don&#x27;t receive a 1900&#x27;s standard of care.<p>Those that I do know who have had cancer were absolutely thankful that someone developed their treatments.</div><br/></div></div></div></div></div></div><div id="39407589" class="c"><input type="checkbox" id="c-39407589" checked=""/><div class="controls bullet"><span class="by">dleavitt</span><span>|</span><a href="#39406368">prev</a><span>|</span><a href="#39406288">next</a><span>|</span><label class="collapse" for="c-39407589">[-]</label><label class="expand" for="c-39407589">[1 more]</label></div><br/><div class="children"><div class="content">The article didn&#x27;t focus too much on solutions, though a couple of things were mentioned:
1. Reducing patent protection
2. Price controls (?)<p>So let&#x27;s assume we want these companies to reduce their profit margins (and instead lower drug prices or spend more on R&amp;D.) What _are_ the best policy tools to incentivize this while minimizing market distortions, etc?</div><br/></div></div><div id="39406288" class="c"><input type="checkbox" id="c-39406288" checked=""/><div class="controls bullet"><span class="by">mdorazio</span><span>|</span><a href="#39407589">prev</a><span>|</span><a href="#39407504">next</a><span>|</span><label class="collapse" for="c-39406288">[-]</label><label class="expand" for="c-39406288">[8 more]</label></div><br/><div class="children"><div class="content">So... what is Congress actually going to do about it? Fix the broken patent system? Put a ceiling on pharma profits the same way health insurance profits are limited (80&#x2F;20 rule)? Or just point fingers and continue taking campaign donation checks?</div><br/><div id="39406317" class="c"><input type="checkbox" id="c-39406317" checked=""/><div class="controls bullet"><span class="by">toomuchtodo</span><span>|</span><a href="#39406288">parent</a><span>|</span><a href="#39406729">next</a><span>|</span><label class="collapse" for="c-39406317">[-]</label><label class="expand" for="c-39406317">[1 more]</label></div><br/><div class="children"><div class="content"><a href="https:&#x2F;&#x2F;www.hhs.gov&#x2F;about&#x2F;news&#x2F;2023&#x2F;08&#x2F;29&#x2F;hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html" rel="nofollow">https:&#x2F;&#x2F;www.hhs.gov&#x2F;about&#x2F;news&#x2F;2023&#x2F;08&#x2F;29&#x2F;hhs-selects-the-fi...</a> (&quot;HHS Selects the First Drugs for Medicare Drug Price Negotiation&quot;)<p><a href="https:&#x2F;&#x2F;finance.yahoo.com&#x2F;news&#x2F;pharmaceutical-groups-lawsuit-over-medicare-030745838.html" rel="nofollow">https:&#x2F;&#x2F;finance.yahoo.com&#x2F;news&#x2F;pharmaceutical-groups-lawsuit...</a> (&quot;Pharmaceutical group&#x27;s lawsuit over Medicare drug price program dismissed&quot;)<p>Jon Stewart says it best (because of course he does): <a href="https:&#x2F;&#x2F;youtu.be&#x2F;NpBPm0b9deQ?t=1153" rel="nofollow">https:&#x2F;&#x2F;youtu.be&#x2F;NpBPm0b9deQ?t=1153</a><p>&quot;The work of making this world resemble one that you would prefer to live in is a lunch pail [bleep] job, day in and day out, where thousands of committed, anonymous, smart, and dedicated people bang on closed doors and pick up those that are fallen and grind away on issues till they get a positive result.&quot;<p>You keep on grinding.<p>&gt; The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare Part D, Medicare’s outpatient prescription drug benefit program, and Medicare Part B, which covers physician and outpatient services, including drugs administered by physicians and other providers. Under the new Medicare Drug Price Negotiation Program, the number of drugs subject to price negotiation will be limited to 10 Part D drugs for 2026, another 15 Part D drugs for 2027, another 15 Part D and Part B drugs for 2028, and another 20 Part D and Part B drugs for 2029 and later years. The number of drugs with negotiated prices available will accumulate over time.<p><a href="https:&#x2F;&#x2F;www.kff.org&#x2F;medicare&#x2F;issue-brief&#x2F;a-small-number-of-drugs-account-for-a-large-share-of-medicare-part-d-spending&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.kff.org&#x2F;medicare&#x2F;issue-brief&#x2F;a-small-number-of-d...</a></div><br/></div></div><div id="39406729" class="c"><input type="checkbox" id="c-39406729" checked=""/><div class="controls bullet"><span class="by">petre</span><span>|</span><a href="#39406288">parent</a><span>|</span><a href="#39406317">prev</a><span>|</span><a href="#39406305">next</a><span>|</span><label class="collapse" for="c-39406729">[-]</label><label class="expand" for="c-39406729">[1 more]</label></div><br/><div class="children"><div class="content">France caps the prices the state is willing to pay, so the drugs are compensated through state owned health insurance if the company isn&#x27;t selling much. Not all of them are 100% covered, but one can additionaly buy private insurance to cover everything.</div><br/></div></div><div id="39406305" class="c"><input type="checkbox" id="c-39406305" checked=""/><div class="controls bullet"><span class="by">catchnear4321</span><span>|</span><a href="#39406288">parent</a><span>|</span><a href="#39406729">prev</a><span>|</span><a href="#39407504">next</a><span>|</span><label class="collapse" for="c-39406305">[-]</label><label class="expand" for="c-39406305">[5 more]</label></div><br/><div class="children"><div class="content">they will continue to beat the markets.<p>(not because they cheat, because they are our betters.)</div><br/><div id="39406426" class="c"><input type="checkbox" id="c-39406426" checked=""/><div class="controls bullet"><span class="by">transcriptase</span><span>|</span><a href="#39406288">root</a><span>|</span><a href="#39406305">parent</a><span>|</span><a href="#39407504">next</a><span>|</span><label class="collapse" for="c-39406426">[-]</label><label class="expand" for="c-39406426">[4 more]</label></div><br/><div class="children"><div class="content">Nancy Pelosi’s success at options trading at 83 years old is really quite remarkable.<p>Imagine having returns that dunk on even the best financial minds on Wall Street as an octogenarian congresswoman nailing calls on tech stocks. I guess the rest of us just have a “skill issue” as the kids say.</div><br/><div id="39406478" class="c"><input type="checkbox" id="c-39406478" checked=""/><div class="controls bullet"><span class="by">jamiek88</span><span>|</span><a href="#39406288">root</a><span>|</span><a href="#39406426">parent</a><span>|</span><a href="#39406453">next</a><span>|</span><label class="collapse" for="c-39406478">[-]</label><label class="expand" for="c-39406478">[1 more]</label></div><br/><div class="children"><div class="content">She&#x27;s an amateur and is actually married to a hedgie, look up how much Mitch McConnell has made.</div><br/></div></div><div id="39406453" class="c"><input type="checkbox" id="c-39406453" checked=""/><div class="controls bullet"><span class="by">ceejayoz</span><span>|</span><a href="#39406288">root</a><span>|</span><a href="#39406426">parent</a><span>|</span><a href="#39406478">prev</a><span>|</span><a href="#39406449">next</a><span>|</span><label class="collapse" for="c-39406453">[-]</label><label class="expand" for="c-39406453">[1 more]</label></div><br/><div class="children"><div class="content">The rest of us aren’t married to a prominent VC from whom much of the wealth originates.</div><br/></div></div><div id="39406449" class="c"><input type="checkbox" id="c-39406449" checked=""/><div class="controls bullet"><span class="by">defrost</span><span>|</span><a href="#39406288">root</a><span>|</span><a href="#39406426">parent</a><span>|</span><a href="#39406453">prev</a><span>|</span><a href="#39407504">next</a><span>|</span><label class="collapse" for="c-39406449">[-]</label><label class="expand" for="c-39406449">[1 more]</label></div><br/><div class="children"><div class="content">Imagine marrying a twenty year younger venture capitalist toy boy to manage her finances for her .. that&#x27;s likely to be the remarkable secret sauce.</div><br/></div></div></div></div></div></div></div></div><div id="39407504" class="c"><input type="checkbox" id="c-39407504" checked=""/><div class="controls bullet"><span class="by">abhisheksingh01</span><span>|</span><a href="#39406288">prev</a><span>|</span><a href="#39407143">next</a><span>|</span><label class="collapse" for="c-39407504">[-]</label><label class="expand" for="c-39407504">[1 more]</label></div><br/><div class="children"><div class="content">I read somewhere that the amount of money that Pharma companies spend on research is the highest in healthcare but they get only about ~13% of the healthcare&#x27;s revenue. There are other middle-man in healthcare that get a revenue share without putting in any work.<p>This is obviously not to say that Big Pharma cannot do better and there are no red flags.</div><br/></div></div><div id="39407143" class="c"><input type="checkbox" id="c-39407143" checked=""/><div class="controls bullet"><span class="by">anonzzzies</span><span>|</span><a href="#39407504">prev</a><span>|</span><a href="#39407519">next</a><span>|</span><label class="collapse" for="c-39407143">[-]</label><label class="expand" for="c-39407143">[1 more]</label></div><br/><div class="children"><div class="content">I think everyone here knows how big pharma works (well, doesn’t ‘work’ as such) however this needs to get into the press a lot more for the public to see.</div><br/></div></div><div id="39407519" class="c"><input type="checkbox" id="c-39407519" checked=""/><div class="controls bullet"><span class="by">ajuc</span><span>|</span><a href="#39407143">prev</a><span>|</span><a href="#39407121">next</a><span>|</span><label class="collapse" for="c-39407519">[-]</label><label class="expand" for="c-39407519">[1 more]</label></div><br/><div class="children"><div class="content">I grew up as an enthusiast of free market capitalism without regulation (probably because my country was just exiting communism when I was 7 and I&#x27;ve seen what good free market reforms can bring).<p>But over last 15 years I&#x27;ve moved significantly towards free market social welfare state. It&#x27;s true that central planning doesn&#x27;t work, and that communism doesn&#x27;t work. It&#x27;s painfully obvious to anybody who lived it. But capitalism leads to results just as bad if left unchecked for too long. It&#x27;s just getting there slower than other systems. Even the rules we add don&#x27;t stop it, they only slow down the gradual descent into oligarchy. At which point it doesn&#x27;t matter what the rules are - because the oligarchs are choosing presidents, PMs and judges.<p>Now I think the perfect economic system would be free market capitalism for 50 years, then a total nationalisation of everything, reshuffle and restart. Rinse and repeat.<p>Capitalism is like a game of football that lasts forever. No matter what you do, if you&#x27;re born into Real Madrid you&#x27;ll win, because the score is already 1000000000-10. There&#x27;s a reason we restart the scores after every game.</div><br/></div></div><div id="39407121" class="c"><input type="checkbox" id="c-39407121" checked=""/><div class="controls bullet"><span class="by">missedthecue</span><span>|</span><a href="#39407519">prev</a><span>|</span><a href="#39407325">next</a><span>|</span><label class="collapse" for="c-39407121">[-]</label><label class="expand" for="c-39407121">[1 more]</label></div><br/><div class="children"><div class="content">I think a lot of laypeople have the idea that there are an infinite number of positive return projects waiting to be funded and pharma execs are just too fat and greedy.<p>There are very few pharma projects that aren&#x27;t outright frauds and that actually have potential and that don&#x27;t cost way more to get to market than they can ever possibly justify.<p>Very seldom do those project lack money.</div><br/></div></div><div id="39407325" class="c"><input type="checkbox" id="c-39407325" checked=""/><div class="controls bullet"><span class="by">__loam</span><span>|</span><a href="#39407121">prev</a><span>|</span><a href="#39406328">next</a><span>|</span><label class="collapse" for="c-39407325">[-]</label><label class="expand" for="c-39407325">[1 more]</label></div><br/><div class="children"><div class="content">Amgen is basically a finance firm that does drug development as a hobby.</div><br/></div></div><div id="39406328" class="c"><input type="checkbox" id="c-39406328" checked=""/><div class="controls bullet"><span class="by">anonym29</span><span>|</span><a href="#39407325">prev</a><span>|</span><a href="#39406178">next</a><span>|</span><label class="collapse" for="c-39406328">[-]</label><label class="expand" for="c-39406328">[1 more]</label></div><br/><div class="children"><div class="content">Now compare R&amp;D and exec&#x2F;shareholder pay to expenditure on &quot;lobbying&quot; (i.e. legalized bribery) and corporate capture of the &quot;strong&quot; and &quot;independent&quot; government regulatory agencies that were meant to keep these very same companies in line.</div><br/></div></div><div id="39406178" class="c"><input type="checkbox" id="c-39406178" checked=""/><div class="controls bullet"><span class="by">Solvency</span><span>|</span><a href="#39406328">prev</a><span>|</span><a href="#39407388">next</a><span>|</span><label class="collapse" for="c-39406178">[-]</label><label class="expand" for="c-39406178">[10 more]</label></div><br/><div class="children"><div class="content">You can write this article about the vast majority of corporations.</div><br/><div id="39406262" class="c"><input type="checkbox" id="c-39406262" checked=""/><div class="controls bullet"><span class="by">toomuchtodo</span><span>|</span><a href="#39406178">parent</a><span>|</span><a href="#39407388">next</a><span>|</span><label class="collapse" for="c-39406262">[-]</label><label class="expand" for="c-39406262">[9 more]</label></div><br/><div class="children"><div class="content">You eat an elephant one bite at a time. If we’re gonna start anywhere, pharmaceutical companies are a fine place to compress margins. You know, because people need these products to survive, and corporate existence as well as profits aren’t guaranteed.<p>We can always come for additional sectors in the future, depending on objectives and resourcing.</div><br/><div id="39406336" class="c"><input type="checkbox" id="c-39406336" checked=""/><div class="controls bullet"><span class="by">anonym29</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406262">parent</a><span>|</span><a href="#39407512">next</a><span>|</span><label class="collapse" for="c-39406336">[-]</label><label class="expand" for="c-39406336">[7 more]</label></div><br/><div class="children"><div class="content">Why don&#x27;t the scientists actually doing the work of drug discovery just start a not-for-profit, since the executives and shareholders aren&#x27;t actually adding any value to the customers here?</div><br/><div id="39406345" class="c"><input type="checkbox" id="c-39406345" checked=""/><div class="controls bullet"><span class="by">toomuchtodo</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406336">parent</a><span>|</span><a href="#39407072">next</a><span>|</span><label class="collapse" for="c-39406345">[-]</label><label class="expand" for="c-39406345">[2 more]</label></div><br/><div class="children"><div class="content">Do you mean the NSF and NIH? Certainly, fund them with what currently goes to pharma for executives, shareholders, lobbying, and marketing. Fund meaningful work, not gravy for corporate performance artists (Part D is funded by general revenues, beneficiary premiums, and state contributions).<p>Cut out the middleman.<p>&quot;In 2021, Medicare Part D covered more than 3,500 prescription drug products, with total gross spending of $216 billion, not accounting for rebates paid by drug manufacturers to pharmacy benefit managers (PBMs).&quot;<p><a href="https:&#x2F;&#x2F;www.kff.org&#x2F;medicare&#x2F;issue-brief&#x2F;a-small-number-of-drugs-account-for-a-large-share-of-medicare-part-d-spending&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.kff.org&#x2F;medicare&#x2F;issue-brief&#x2F;a-small-number-of-d...</a><p>From this post:<p>&gt; Peter Maybarduk, the director of the Access to Medicines program at Public Citizen, a watchdog organization, who also testified at the hearing, hit back at the main pharmaceutical talking points along with Sanders. That included noting that the makers of the 10 drugs selected for the first round of  Medicare price negotiation spent $10 billion more on self-enriching activities than R&amp;D.<p>($200B&#x2F;year buys a lot of manufacturing, distribution, admin, and whatever is left over for amortized and ongoing R&amp;D)</div><br/><div id="39407097" class="c"><input type="checkbox" id="c-39407097" checked=""/><div class="controls bullet"><span class="by">pompino</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406345">parent</a><span>|</span><a href="#39407072">next</a><span>|</span><label class="collapse" for="c-39407097">[-]</label><label class="expand" for="c-39407097">[1 more]</label></div><br/><div class="children"><div class="content">&gt;Fund meaningful work, not gravy for corporate performance artists (Part D is funded by general revenues, beneficiary premiums, and state contributions).<p>The problem is that nobody actually knows or can predict what &quot;meaningful work&quot; is because drug discovery is a graveyard with a &gt;90% death rate.</div><br/></div></div></div></div><div id="39407072" class="c"><input type="checkbox" id="c-39407072" checked=""/><div class="controls bullet"><span class="by">pompino</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406336">parent</a><span>|</span><a href="#39406345">prev</a><span>|</span><a href="#39406701">next</a><span>|</span><label class="collapse" for="c-39407072">[-]</label><label class="expand" for="c-39407072">[1 more]</label></div><br/><div class="children"><div class="content">Because fundamentally most of science is a dead-end. Most of drug discovery is a further dead end with a 90% failure rate. Nobody wants to pay for it, and big-pharma uses a few blockbuster products to pay for all their other failures.</div><br/></div></div><div id="39406701" class="c"><input type="checkbox" id="c-39406701" checked=""/><div class="controls bullet"><span class="by">asadotzler</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406336">parent</a><span>|</span><a href="#39407072">prev</a><span>|</span><a href="#39406407">next</a><span>|</span><label class="collapse" for="c-39406701">[-]</label><label class="expand" for="c-39406701">[1 more]</label></div><br/><div class="children"><div class="content">They did. They work for the US Government which does all the work of drug discovery which gets handed off, along with huge grants and other benefits, to private companies to productive and then sell at ridiculous profits that fuel massive executive pay packages and huge buybacks. The rich get richer while the taxpayers and most users of the ultimate product get screwed. It&#x27;s really that simple.</div><br/></div></div><div id="39406407" class="c"><input type="checkbox" id="c-39406407" checked=""/><div class="controls bullet"><span class="by">Sabinus</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406336">parent</a><span>|</span><a href="#39406701">prev</a><span>|</span><a href="#39406587">next</a><span>|</span><label class="collapse" for="c-39406407">[-]</label><label class="expand" for="c-39406407">[1 more]</label></div><br/><div class="children"><div class="content">Because drug discovery needs patient trials, and the massive cost of those trails drives scientists into the arms of investors and the for-profit sector.</div><br/></div></div><div id="39406587" class="c"><input type="checkbox" id="c-39406587" checked=""/><div class="controls bullet"><span class="by">aaomidi</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406336">parent</a><span>|</span><a href="#39406407">prev</a><span>|</span><a href="#39407512">next</a><span>|</span><label class="collapse" for="c-39406587">[-]</label><label class="expand" for="c-39406587">[1 more]</label></div><br/><div class="children"><div class="content">not-for-profit companies are subject to a lot of bullshittery too.</div><br/></div></div></div></div><div id="39407512" class="c"><input type="checkbox" id="c-39407512" checked=""/><div class="controls bullet"><span class="by">carlosjobim</span><span>|</span><a href="#39406178">root</a><span>|</span><a href="#39406262">parent</a><span>|</span><a href="#39406336">prev</a><span>|</span><a href="#39407388">next</a><span>|</span><label class="collapse" for="c-39407512">[-]</label><label class="expand" for="c-39407512">[1 more]</label></div><br/><div class="children"><div class="content">You&#x27;re speaking as if you were a movie villain or a communist dictator. Pure day dreaming.</div><br/></div></div></div></div></div></div><div id="39407388" class="c"><input type="checkbox" id="c-39407388" checked=""/><div class="controls bullet"><span class="by">jollyoldpirate</span><span>|</span><a href="#39406178">prev</a><span>|</span><a href="#39406327">next</a><span>|</span><label class="collapse" for="c-39407388">[-]</label><label class="expand" for="c-39407388">[2 more]</label></div><br/><div class="children"><div class="content">If only HN would get up in arms about this the way they do about Putin. Think of the change you could make!</div><br/><div id="39407403" class="c"><input type="checkbox" id="c-39407403" checked=""/><div class="controls bullet"><span class="by">Retr0id</span><span>|</span><a href="#39407388">parent</a><span>|</span><a href="#39406327">next</a><span>|</span><label class="collapse" for="c-39407403">[-]</label><label class="expand" for="c-39407403">[1 more]</label></div><br/><div class="children"><div class="content">Maybe it&#x27;s just the threads I click on, but I can&#x27;t recall the last time I even saw Putin mentioned on HN.</div><br/></div></div></div></div><div id="39406327" class="c"><input type="checkbox" id="c-39406327" checked=""/><div class="controls bullet"><span class="by">refurb</span><span>|</span><a href="#39407388">prev</a><span>|</span><a href="#39406315">next</a><span>|</span><label class="collapse" for="c-39406327">[-]</label><label class="expand" for="c-39406327">[6 more]</label></div><br/><div class="children"><div class="content"><i>That year, the company spent $17.8 billion on stock buybacks, dividends, and executive compensation, while the company spent just $14.6 billion on R&amp;D, the report states. &quot;In other words, the company spent $3.2 billion more enriching executives and stockholders than finding new cures,&quot; it concludes.</i><p>This is such a bizarre criticism.  Note they include executive compensation, despite it being $26M out of the $14.6B (0.15%).  And &quot;spending&quot; on dividends?  You mean &quot;returning money to shareholders&quot;.<p>How do they think businesses work?<p>And since I have a 401k invested in index funds, <i>I&#x27;m a shareholder</i>.  So the criticism of &quot;spending on shareholders&quot; they actually mean &quot;vast swaths of Americans whose retirement and pensions are invested in the stock market&quot;.</div><br/><div id="39406448" class="c"><input type="checkbox" id="c-39406448" checked=""/><div class="controls bullet"><span class="by">consp</span><span>|</span><a href="#39406327">parent</a><span>|</span><a href="#39406315">next</a><span>|</span><label class="collapse" for="c-39406448">[-]</label><label class="expand" for="c-39406448">[5 more]</label></div><br/><div class="children"><div class="content">&gt; returning money to shareholders<p>There is nothing to return. Handing out is what it is.<p>&gt; And since I have a 401k invested in index funds, I&#x27;m a shareholder. So the criticism of &quot;spending on shareholders&quot; they actually mean &quot;vast swaths of Americans whose retirement and pensions are invested in the stock market<p>This is a common repeated fallacy. Nice for you to profit but this is no whole gain for society.</div><br/><div id="39406711" class="c"><input type="checkbox" id="c-39406711" checked=""/><div class="controls bullet"><span class="by">BenFranklin100</span><span>|</span><a href="#39406327">root</a><span>|</span><a href="#39406448">parent</a><span>|</span><a href="#39406508">next</a><span>|</span><label class="collapse" for="c-39406711">[-]</label><label class="expand" for="c-39406711">[1 more]</label></div><br/><div class="children"><div class="content">The ‘whole gain’ for society is the medications that come out of investors putting money into these companies, instead of, say, Facebook. In 10-15 years, every new medication released today, will be off patent — and with insurance helping with payments taking into consideration — essentially free. Mind you, we are also talking about diseases for which no therapies exist today, and therefore the cost is effectively infinite in 2024.<p>Another point this story glosses over is that the $14.6B spent on R&amp;D, represents nearly 1&#x2F;3 of the entire National Institutes for Health $47B 2023 budget. And this is by a single company.</div><br/></div></div><div id="39406508" class="c"><input type="checkbox" id="c-39406508" checked=""/><div class="controls bullet"><span class="by">throwawayqqq11</span><span>|</span><a href="#39406327">root</a><span>|</span><a href="#39406448">parent</a><span>|</span><a href="#39406711">prev</a><span>|</span><a href="#39406315">next</a><span>|</span><label class="collapse" for="c-39406508">[-]</label><label class="expand" for="c-39406508">[3 more]</label></div><br/><div class="children"><div class="content">Even better, the more ground level and more risky research is often funded publicly, only to be bought or go private, once a product could emerge. Big pharma is hawking over public research.</div><br/><div id="39407012" class="c"><input type="checkbox" id="c-39407012" checked=""/><div class="controls bullet"><span class="by">BenFranklin100</span><span>|</span><a href="#39406327">root</a><span>|</span><a href="#39406508">parent</a><span>|</span><a href="#39406315">next</a><span>|</span><label class="collapse" for="c-39407012">[-]</label><label class="expand" for="c-39407012">[2 more]</label></div><br/><div class="children"><div class="content">This is an oft-repeated sound bite by politicians looking to score cheap points, but it isn’t true.<p><a href="https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;rep-ocasio-cortez-and-where-drugs-come" rel="nofollow">https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;rep-ocasio-cortez-...</a></div><br/><div id="39407213" class="c"><input type="checkbox" id="c-39407213" checked=""/><div class="controls bullet"><span class="by">throwawayqqq11</span><span>|</span><a href="#39406327">root</a><span>|</span><a href="#39407012">parent</a><span>|</span><a href="#39406315">next</a><span>|</span><label class="collapse" for="c-39407213">[-]</label><label class="expand" for="c-39407213">[1 more]</label></div><br/><div class="children"><div class="content">I dont buy it. Your linked blog post is about Derek Lowe gathering anecdotes, mostly.<p>His linked article (a better one)<p><a href="https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;where-drugs-come-numbers" rel="nofollow">https:&#x2F;&#x2F;www.science.org&#x2F;content&#x2F;blog-post&#x2F;where-drugs-come-n...</a><p>is biased, because it only looks at <i>approved</i> drugs. He himself turns slightly to the R&amp;D side and almost gets it.<p>&gt; And now to innovation - 118 of the drugs during this period were considered to have scientific novelty (46%), and of those:<p>&gt; 44% were from pharmaceutical companies.<p>&gt; 25% were from biotech companies, and<p>&gt; 31% were from universities (transferred to either biotech or pharma).<p>&gt; The university-derived drugs clearly outperform in this category. What this also means is that 65% of the pharma-derived drugs get classed as &quot;not innovative&quot;<p>To be fair, i dont think you can convince me, that the pharma industry has no incentive to externalize risky or less profitable research and would never do it.<p>I have one anecdote for you too, hitting that exact spot: anti-biotics research. Because even though it has good prospect for profit, it is too risky research (kind of diminishing returns of R&amp;D in that area).<p><a href="https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC7872909&#x2F;" rel="nofollow">https:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC7872909&#x2F;</a></div><br/></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></body></html>